Search | IOVS | ARVO Journals

View

Showing 1 – 18 of 18

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2019

Outcomes of cataract surgery in patient with wet age-related macular degeneration while being treated with intravitreal Aflibercept with treat-and-extend regimen.

Tatsuya Nagai; Tomohiro Nizawa; Masayasu Kitahashi; Takayuki Baba; Shuichi Yamamoto; Takehito Iwase

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):88. doi:

ARVO Annual Meeting Abstract July 2018

Long-term results of photodynamic therapy for circumscribed choroidal hemangioma

Yuko Hayashi; Masayasu Kitahashi; Takayuki Baba; Tomohiro Nizawa; Mariko Kubota; Shuichi Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5592. doi:

ARVO Annual Meeting Abstract June 2017

Retinal Sensitivity Reduced in Patients with Multiple Sclerosis with no History of Optic Neuritis

kanako suzuki; Hirotaka Yokouchi; Toshiyuki Oshitari; Masayasu Kitahashi; Takayuki Baba; Shuichi Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5116. doi:

ARVO Annual Meeting Abstract September 2016

One year outcomes of intravitreal aflibercept for wet AMD using modified treat and extend regimen

Tomohiro Nizawa; Masayasu Kitahashi; Hirotaka Yokouchi; Mariko Kubota; Takayuki Baba; Shuichi Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2669. doi:

ARVO Annual Meeting Abstract April 2014

Two-year Outcome of Half-time Reduced Fluence Photodynamic Therapy Combined with Intravitreal Ranibizumab for Retinal Angiomatous Proliferation

Akihiro Chiba; Hirotaka Yokouchi; Masayasu Kitahashi; Mariko Kubota; Takayuki Baba; Shuichi Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):4943. doi:

ARVO Annual Meeting Abstract April 2014

Retinal Sensitivity Changes After Half-time Reduced-Fluence Photodynamic Therapy for Central Serous Chorioretinopathy

Hirotaka Yokouchi; Masayasu Kitahashi; Mariko Kubota; Takayuki Baba; Shuichi Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):6375. doi:

ARVO Annual Meeting Abstract June 2013

Level of vascular endothelial growth factor 165b in human aqueous humor

Takayuki Baba; Guzel Bikbova; Masayasu Kitahashi; Hirotaka Yokouchi; Madoka Sakurai; Mariko Kubota-Taniai; Shuichi Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4121. doi:

ARVO Annual Meeting Abstract June 2013

Long-term Results of Combination Therapy with Half-time Reduced Fluence Photodynamic Therapy and Intravitreal Ranibizumab for Retinal Angiomatous Proliferation

Hirotaka Yokouchi; Masayasu Kitahashi; Madoka Sakurai; Mariko Kubota-Taniai; Takayuki Baba; Shuichi Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3792. doi:

ARVO Annual Meeting Abstract June 2013

One-year Results of Intravitreal Ranibizumab Combined with Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

daisuke yamanouchi; Madoka Sakurai; Takayuki Baba; Masayasu Kitahashi; Hirotaka Yokouchi; Mariko Kubota-Taniai; Shuichi Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4626. doi:

ARVO Annual Meeting Abstract March 2012

Short-term Outcome of Combined Reduced Fluence Photodynamic Therapy and Intravitreal Ranibizumab for Retinal Angiomatous Proliferation

Fusae Kajita; Masayasu Kitahashi; Madoka Sakurai; Hironori Yokouchi; Mariko Kubota; Takayuki Baba; Shuichi Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5151. doi:

ARVO Annual Meeting Abstract March 2012

Therapeutic Efficacy of Intravitreal Ranibizumab Combined with Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

Madoka Sakurai; Masayasu Kitahashi; Hirotaka Yokouchi; Takayuki Baba; Mariko Kubota-Taniai; Syuichi Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2062. doi:

ARVO Annual Meeting Abstract March 2012

Pneumatic Displacement Combined with Intravitreal Bevacizumab for Massive Submacular Hemorrhage due to Polypoidal Choroidal Vasculopathy

Masayasu Kitahashi; Takayuki Baba; Madoka Sakurai-Yanagihashi; Hirotaka Yokouchi; Mariko Kubota-Taniai; Yoshinori Mitamura; Shuichi Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2064. doi:

ARVO Annual Meeting Abstract April 2011

Two-year Follow-up Of Subfoveal Pigment Epithelial Detachment In Eyes With Age-related Macular Degeneration And Visual Acuity Better Than 20/40

Takayuki Baba; Masayasu Kitahashi; Mariko Kubota-Taniai; Emi Ohoka; Shuichi Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1679. doi:

ARVO Annual Meeting Abstract April 2010

Correlation Between Foveal Outer Nuclear Layer Thickness and Visual Acuity in Eyes With Submacular Hemorrhage Treated With Intravitreal Bevacizumab and Pneumatic Displacement

S. Yamamoto; M. Kitahashi; E. Ohoka; M. Kubota-Taniai; Y. Mitamura

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):3613. doi:

ARVO Annual Meeting Abstract April 2009

Two Year Results of Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

G. Miura; M. Kitahashi; M. Kubota; Y. Mitamura; S. Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):242. doi:

ARVO Annual Meeting Abstract May 2008

Changes of Retinal Sensitivity and Thickness of Macula After Photodynamic Therapy for Age-Related Macular Degeneration

S. Yamamoto; K. Okada; M. Kubota-Taniai; M. Kitahashi; T. Baba; Y. Mitamura

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):255. doi:

ARVO Annual Meeting Abstract May 2008

Comparison of Intravitreal Bevacizumab to Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

Y. Mitamura; M. Kitahashi; K. Okada; T. Baba; M. Kubota-Taniai; S. Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):303. doi:

ARVO Annual Meeting Abstract May 2008

Combined Intravitreal Gas Injection and Intravitreal Bevacizumab for Massive Submacular Hemorrhage Due to Polypoidal Choroidal Vasculopathy

M. Kitahashi; M. Kubota-Taniai; T. Baba; Y. Mitamura; S. Yamamoto

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):5611. doi:

Advertisement